PMID- 31353982
OWN - NLM
STAT- MEDLINE
DCOM- 20190904
LR  - 20190904
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 18
IP  - 9
DP  - 2019 Sep
TI  - A drug safety evaluation of abiraterone acetate in the treatment of prostate 
      cancer.
PG  - 759-767
LID - 10.1080/14740338.2019.1648428 [doi]
AB  - Introduction: To evaluate the safety profile characteristics of abiraterone 
      acetate (AA) in the treatment of metastatic prostate cancer (mPCa). Areas 
      covered: In this literature review the authors evaluate safety data from phase 
      III trials investigating the combination of abiraterone acetate plus prednisone 
      (AAP) in patients with metastatic prostate cancer. In particular, the aim was to 
      clarify its toxicity profile, long-term exposure impact, and the correlation with 
      general health-related quality of life (HRQoL). Expert opinion: Based on the 
      studies reviewed, it appears that abiraterone acetate has favourable outcomes, is 
      effective and well tolerated, mostly in asymptomatic or slightly symptomatic 
      patients, and has recognised toxicity profile characteristics. Incidence of 
      adverse events (AEs), such as mineralocorticoid- and corticosteroid-releated AEs, 
      and hepatotoxicity is well known and widely described. Understanding the toxicity 
      profile of AA could assist decision-making in clinical practice.
FAU - Castellan, Pietro
AU  - Castellan P
AUID- ORCID: 0000-0002-1559-0117
AD  - a Department of Urology, SS. Annunziata Hospital , Chieti , Italy.
FAU - Castellucci, Roberto
AU  - Castellucci R
AD  - a Department of Urology, SS. Annunziata Hospital , Chieti , Italy.
FAU - Marchioni, Michele
AU  - Marchioni M
AUID- ORCID: 0000-0002-1702-4127
AD  - b Department of Urology, University "G. d'Annunzio" , Chieti , Italy.
FAU - De Nunzio, Cosimo
AU  - De Nunzio C
AD  - c Department of Urology, Sant'Andrea Hospital, University "La Sapienza" , Rome , 
      Italy.
FAU - Tema, Giorgia
AU  - Tema G
AD  - c Department of Urology, Sant'Andrea Hospital, University "La Sapienza" , Rome , 
      Italy.
FAU - Primiceri, Giulia
AU  - Primiceri G
AD  - b Department of Urology, University "G. d'Annunzio" , Chieti , Italy.
FAU - Schips, Luigi
AU  - Schips L
AD  - a Department of Urology, SS. Annunziata Hospital , Chieti , Italy.
AD  - b Department of Urology, University "G. d'Annunzio" , Chieti , Italy.
FAU - Cindolo, Luca
AU  - Cindolo L
AD  - a Department of Urology, SS. Annunziata Hospital , Chieti , Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antineoplastic Agents)
RN  - EM5OCB9YJ6 (Abiraterone Acetate)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Abiraterone Acetate/*administration & dosage/adverse effects
MH  - Antineoplastic Agents
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects
MH  - Humans
MH  - Male
MH  - Neoplasm Metastasis
MH  - Prednisone/administration & dosage
MH  - Prostatic Neoplasms/*drug therapy/pathology
MH  - Quality of Life
OTO - NOTNLM
OT  - Abiraterone acetate
OT  - androgen receptor
OT  - castration-resistant prostate cancer
OT  - hormone-naive prostate cancer
OT  - metastatic prostate cancer
OT  - toxicity
EDAT- 2019/07/30 06:00
MHDA- 2019/09/05 06:00
CRDT- 2019/07/30 06:00
PHST- 2019/07/30 06:00 [pubmed]
PHST- 2019/09/05 06:00 [medline]
PHST- 2019/07/30 06:00 [entrez]
AID - 10.1080/14740338.2019.1648428 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2019 Sep;18(9):759-767. doi: 10.1080/14740338.2019.1648428.